The graft versus host disease (gvhd) treatment market size has grown strongly in recent years. It will grow from $3.06 billion in 2025 to $3.29 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to bone marrow transplant adoption, corticosteroid availability, hospital oncology expansion, immunosuppressive drug development, transplant survival improvement.
The graft versus host disease (gvhd) treatment market size is expected to see strong growth in the next few years. It will grow to $4.21 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to biologic therapy pipeline growth, personalized immunosuppression, transplant procedure volume increase, orphan drug incentives, specialty care expansion. Major trends in the forecast period include increased use of targeted immunotherapies, growth of biologic treatment adoption, rising focus on chronic gvhd management, expansion of stem cell transplant programs, increased clinical trial activity.
The increasing prevalence of hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the coming years. Hematological disorders, or blood disorders, include a broad range of conditions affecting the blood and its components, such as red blood cells, white blood cells, platelets, and plasma. The rise in hematological disorders is linked to factors like unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins, including radiation, chemicals, and pollutants. GVHD treatment strategies for managing graft-versus-host disease can offer broader benefits for patients with blood disorders by providing new approaches for immune modulation and improved disease management. For example, in 2023, according to the Leukemia & Lymphoma Society, a US-based healthcare organization, leukemia, lymphoma, and myeloma are expected to cause approximately 57,380 deaths in the US in 2023, which equates to about 157 deaths per day or more than six people every hour. Therefore, the increasing prevalence of hematological disorders is driving the GVHD treatment market.
Key companies in the GVHD treatment market are focusing on developing advanced drugs and securing regulatory approvals to maintain a competitive edge. Product approvals ensure that healthcare therapies meet required standards of safety, efficacy, and quality before being made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor approved by the US Food and Drug Administration. These tablets are intended for once-daily use in treating specific forms of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
In March 2024, Lonza Group Ltd., a Switzerland-based healthcare manufacturing company, acquired Roche’s biologics manufacturing site for $1.2 billion. Through this acquisition, Lonza aims to expand its portfolio by integrating Roche’s expertise in providing graft versus host disease (GVHD) treatments. F. Hoffmann-La Roche AG, based in Switzerland, is a company that specializes in GVHD therapies.
Major companies operating in the graft versus host disease (gvhd) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Mesoblast Ltd., AbbVie Inc., Eli Lilly and Company, CSL Behring Limited, Fate Therapeutics Inc., Orca Bio Inc., BioLineRx Ltd., Xenikos BV, Regeneron Pharmaceuticals Inc., AstraZeneca PLC, Amgen Inc.
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (gvhd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the graft versus host disease (gvhd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the graft versus host disease treatment market by increasing costs of imported biologics, immunosuppressants, and specialty pharmaceuticals. Hospital pharmacies are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising expenses for long-term immunosuppressive therapy and post-transplant care, affecting patient outcomes and healthcare budgets. However, they promote domestic biologics manufacturing, strengthening regional production of complex immunotherapies.
The graft versus host disease (gvhd) treatment market research report is one of a series of new reports that provides graft versus host disease (gvhd) treatment market statistics, including graft versus host disease (gvhd) treatment industry global market size, regional shares, competitors with a graft versus host disease (gvhd) treatment market share, detailed graft versus host disease (gvhd) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the graft versus host disease (gvhd) treatment industry. This graft versus host disease (gvhd) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Graft versus host disease (GVHD) treatment involves medical interventions designed to manage or reduce the complications caused by GVHD, a condition in which transplanted donor cells attack the recipient’s tissues. These treatments aim to control the effects of GVHD and protect the patient from further tissue damage.
The main product types for GVHD treatment include corticosteroids, monoclonal antibodies, immunosuppressants, and others. Corticosteroids are steroid hormones produced in the adrenal cortex of vertebrates, as well as their synthetic analogs. The main disease types addressed are acute GVHD, prophylactic GVHD, and chronic GVHD. These treatments are utilized by end users such as hospital pharmacies, retail pharmacies, and online pharmacies.
The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The graft versus host disease (gvhd) treatment market size is expected to see strong growth in the next few years. It will grow to $4.21 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to biologic therapy pipeline growth, personalized immunosuppression, transplant procedure volume increase, orphan drug incentives, specialty care expansion. Major trends in the forecast period include increased use of targeted immunotherapies, growth of biologic treatment adoption, rising focus on chronic gvhd management, expansion of stem cell transplant programs, increased clinical trial activity.
The increasing prevalence of hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the coming years. Hematological disorders, or blood disorders, include a broad range of conditions affecting the blood and its components, such as red blood cells, white blood cells, platelets, and plasma. The rise in hematological disorders is linked to factors like unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins, including radiation, chemicals, and pollutants. GVHD treatment strategies for managing graft-versus-host disease can offer broader benefits for patients with blood disorders by providing new approaches for immune modulation and improved disease management. For example, in 2023, according to the Leukemia & Lymphoma Society, a US-based healthcare organization, leukemia, lymphoma, and myeloma are expected to cause approximately 57,380 deaths in the US in 2023, which equates to about 157 deaths per day or more than six people every hour. Therefore, the increasing prevalence of hematological disorders is driving the GVHD treatment market.
Key companies in the GVHD treatment market are focusing on developing advanced drugs and securing regulatory approvals to maintain a competitive edge. Product approvals ensure that healthcare therapies meet required standards of safety, efficacy, and quality before being made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor approved by the US Food and Drug Administration. These tablets are intended for once-daily use in treating specific forms of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
In March 2024, Lonza Group Ltd., a Switzerland-based healthcare manufacturing company, acquired Roche’s biologics manufacturing site for $1.2 billion. Through this acquisition, Lonza aims to expand its portfolio by integrating Roche’s expertise in providing graft versus host disease (GVHD) treatments. F. Hoffmann-La Roche AG, based in Switzerland, is a company that specializes in GVHD therapies.
Major companies operating in the graft versus host disease (gvhd) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Mesoblast Ltd., AbbVie Inc., Eli Lilly and Company, CSL Behring Limited, Fate Therapeutics Inc., Orca Bio Inc., BioLineRx Ltd., Xenikos BV, Regeneron Pharmaceuticals Inc., AstraZeneca PLC, Amgen Inc.
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (gvhd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the graft versus host disease (gvhd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the graft versus host disease treatment market by increasing costs of imported biologics, immunosuppressants, and specialty pharmaceuticals. Hospital pharmacies are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising expenses for long-term immunosuppressive therapy and post-transplant care, affecting patient outcomes and healthcare budgets. However, they promote domestic biologics manufacturing, strengthening regional production of complex immunotherapies.
The graft versus host disease (gvhd) treatment market research report is one of a series of new reports that provides graft versus host disease (gvhd) treatment market statistics, including graft versus host disease (gvhd) treatment industry global market size, regional shares, competitors with a graft versus host disease (gvhd) treatment market share, detailed graft versus host disease (gvhd) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the graft versus host disease (gvhd) treatment industry. This graft versus host disease (gvhd) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Graft versus host disease (GVHD) treatment involves medical interventions designed to manage or reduce the complications caused by GVHD, a condition in which transplanted donor cells attack the recipient’s tissues. These treatments aim to control the effects of GVHD and protect the patient from further tissue damage.
The main product types for GVHD treatment include corticosteroids, monoclonal antibodies, immunosuppressants, and others. Corticosteroids are steroid hormones produced in the adrenal cortex of vertebrates, as well as their synthetic analogs. The main disease types addressed are acute GVHD, prophylactic GVHD, and chronic GVHD. These treatments are utilized by end users such as hospital pharmacies, retail pharmacies, and online pharmacies.
The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Graft Versus Host Disease (GVHD) Treatment Market Characteristics
3. Graft Versus Host Disease (GVHD) Treatment Market Supply Chain Analysis
4. Global Graft Versus Host Disease (GVHD) Treatment Market Trends and Strategies
5. Graft Versus Host Disease (GVHD) Treatment Market Analysis of End Use Industries
7. Global Graft Versus Host Disease (GVHD) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Graft Versus Host Disease (GVHD) Treatment Total Addressable Market (TAM) Analysis for the Market
9. Graft Versus Host Disease (GVHD) Treatment Market Segmentation
10. Graft Versus Host Disease (GVHD) Treatment Market Regional and Country Analysis
11. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market
12. China Graft Versus Host Disease (GVHD) Treatment Market
13. India Graft Versus Host Disease (GVHD) Treatment Market
14. Japan Graft Versus Host Disease (GVHD) Treatment Market
15. Australia Graft Versus Host Disease (GVHD) Treatment Market
16. Indonesia Graft Versus Host Disease (GVHD) Treatment Market
17. South Korea Graft Versus Host Disease (GVHD) Treatment Market
18. Taiwan Graft Versus Host Disease (GVHD) Treatment Market
19. South East Asia Graft Versus Host Disease (GVHD) Treatment Market
20. Western Europe Graft Versus Host Disease (GVHD) Treatment Market
21. UK Graft Versus Host Disease (GVHD) Treatment Market
22. Germany Graft Versus Host Disease (GVHD) Treatment Market
23. France Graft Versus Host Disease (GVHD) Treatment Market
24. Italy Graft Versus Host Disease (GVHD) Treatment Market
25. Spain Graft Versus Host Disease (GVHD) Treatment Market
26. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market
27. Russia Graft Versus Host Disease (GVHD) Treatment Market
28. North America Graft Versus Host Disease (GVHD) Treatment Market
29. USA Graft Versus Host Disease (GVHD) Treatment Market
30. Canada Graft Versus Host Disease (GVHD) Treatment Market
31. South America Graft Versus Host Disease (GVHD) Treatment Market
32. Brazil Graft Versus Host Disease (GVHD) Treatment Market
33. Middle East Graft Versus Host Disease (GVHD) Treatment Market
34. Africa Graft Versus Host Disease (GVHD) Treatment Market
36. Graft Versus Host Disease (GVHD) Treatment Market Competitive Landscape and Company Profiles
37. Graft Versus Host Disease (GVHD) Treatment Market Other Major and Innovative Companies
40. Graft Versus Host Disease (GVHD) Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Graft Versus Host Disease (GVHD) Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses graft versus host disease (gvhd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for graft versus host disease (gvhd) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The graft versus host disease (gvhd) treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Corticosteroids; Monoclonal Antibodies; Immunosuppressants; Other Product Types2) By Disease Type: Acute GvHD; Prophylaxis GvHD; Chronic GvHD
3) By End User: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Budesonide2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab); Anti-il-2rα Monoclonal Antibodies ( Basiliximab); Anti-cd52 Monoclonal Antibodies (Alemtuzumab); Anti-il-6 Monoclonal Antibodies (Tocilizumab); Anti-Cd20 Monoclonal Antibodies (Rituximab)
3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus); Methotrexate; Mycophenolate Mofetil; Azathioprine; Sirolimus (Rapamycin); Cyclophosphamide
4) By Other Product Types: Mesenchymal Stem Cells (Mscs); Jak Inhibitors ( Ruxolitinib); Extracorporeal Photopheresis (ECP); Thalidomide; Antithymocyte Globulin (Atg); Colony-Stimulating Factors (Filgrastim)
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi SA; Novartis AG; Bristol Myers Squibb; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Astellas Pharma Inc.; Jazz Pharmaceuticals plc; Incyte Corporation; Mallinckrodt Pharmaceuticals; Mesoblast Ltd.; AbbVie Inc.; Eli Lilly and Company; CSL Behring Limited; Fate Therapeutics Inc.; Orca Bio Inc.; BioLineRx Ltd.; Xenikos BV; Regeneron Pharmaceuticals Inc.; AstraZeneca PLC; Amgen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Graft Versus Host Disease (GVHD) Treatment market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Sanofi SA
- Novartis AG
- Bristol Myers Squibb
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Astellas Pharma Inc.
- Jazz Pharmaceuticals plc
- Incyte Corporation
- Mallinckrodt Pharmaceuticals
- Mesoblast Ltd.
- AbbVie Inc.
- Eli Lilly and Company
- CSL Behring Limited
- Fate Therapeutics Inc.
- Orca Bio Inc.
- BioLineRx Ltd.
- Xenikos BV
- Regeneron Pharmaceuticals Inc.
- AstraZeneca PLC
- Amgen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.29 Billion |
| Forecasted Market Value ( USD | $ 4.21 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
